Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
News
(141)
Filter by form group
Filter by year
2023
(16)
2022
(15)
2021
(18)
2020
(17)
2019
(20)
2018
(11)
2017
(3)
2016
(6)
2015
(13)
2014
(7)
2013
(4)
2012
(3)
2011
(5)
2010
(3)
Search
News
Vaccinex Presented its ActivMAb® Antibody Discovery Technology at the 2014 PEGS Europe Summit
News
Vaccinex Presented data on VX15/2503 at American Society of Clinical Oncology (ASCO) 2014 Conference
News
Vaccinex Appoints Steve Cobourn, C.P.A. as Chief Financial Officer
News
Vaccinex Presented data on VX15/2503 at CRI Cancer Immunotherapy 2013 Conference
News
Vaccinex Presented VX15 Preclinical MS Data at the 2013 ECTRIMS Annual Conference
News
Vaccinex Appoints Valerie Iddison, M.D. as Chief Medical Officer
News
Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients
News
Vaccinex Presented Antibody Selection Technology at the 2012 IBC Antibody Engineering and Antibody Therapeutics Conference
News
Vaccinex to Present VX15 and VX5 Preclinical MS Data at the 2012 ECTRIMS Annual Conference
News
Vaccinex Presented at the American Association for Cancer Research (AACR) Annual Conference
Pagination
Page 1
Next page
››